Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaclp.2021.05.009DOI Listing

Publication Analysis

Top Keywords

integrating payer
4
payer provider
4
provider data
4
data identify
4
identify factors
4
factors associated
4
associated outpatient
4
outpatient psychiatric
4
psychiatric follow-up
4
follow-up inpatient
4

Similar Publications

Introduction: Patient and stakeholder involvement enhances the conduct and applicability of comparative effectiveness research (CER). However, examples of engagement practices for CER leveraging real-world data (i.e.

View Article and Find Full Text PDF

Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World.

Clin Pharmacol Ther

January 2025

Boston Consulting Group, Zurich, Switzerland.

The value of a medicine is defined by its impact on patients, caregivers, health system, and society. A pharmaceutical company will generate evidence to demonstrate this value in various studies, including randomized clinical trials, non-interventional and observational studies, real-world data analyses, modeling, and simulation. The quality and strength of the evidence supporting a medicine's effectiveness, safety and product quality will drive decisions by healthcare system stakeholders for marketing authorization (regulatory authorities).

View Article and Find Full Text PDF

Objectives: Chronic pain is a leading cause of morbidity in children and adolescents globally but can be managed with a combination of traditional Western medicine and integrative medicine (IM) practices. This combination has improved various critical health outcomes, such as quality-of-life, sleep, pain, anxiety, and healthcare utilization. These IM practices include acupuncture, yoga, biofeedback, massage, mindfulness, or any combination of these modalities.

View Article and Find Full Text PDF

Open Ecosystem Through Secure Plug and Play Interoperability: An Overview.

J Diabetes Sci Technol

January 2025

Roche Diabetes Care GmbH, Mannheim, Germany.

Background: Interoperability is a critical enabler for integrated Personalized Diabetes Management (iPDM), automated insulin delivery (AID), and the digital transformation of healthcare in general. However, manufacturers still create closed ecosystems (ie, solutions designed to work end-to-end minimizing collaboration with other organizations) with proprietary interfaces because of various interoperability challenges. Therefore, the aim of this article is to provide an overview of how to achieve organizational interoperability in an open ecosystem (ie, solutions designed to integrate different organizations via interoperability standards) for diabetes management.

View Article and Find Full Text PDF

This study was aimed to evaluate the cost-effectiveness of pembrolizumab with chemotherapy (pembrolizumab combination therapy) and compare it with standard-of-care platinum-based chemotherapy (chemotherapy alone) as a first-line treatment for metastatic nonsquamous NSCLC from the perspective of Taiwan's third-party-payer public health-care system. We used a partitioned survival model with an estimated time horizon of 10 years. The partitioned survival model uses Kaplan-Meier estimates of progression-free and overall survival from the KEYNOTE-189 clinical trial.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!